Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $37.8400 (-3.62%) ($36.9100 - $39.8000) on Wed. Jan. 31, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.64% (three month average) | RSI | 69 | Latest Price | $37.8400(-3.62%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1.4% a day on average for past five trading days. | Weekly Trend | ADMS advances 5.5% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(26%) IBB(24%) IWM(19%) IWO(19%) QQQ(19%) | Factors Impacting ADMS price | ADMS will decline at least -1.82% in a week (0% probabilities). VIXM(-13%) UNG(-9%) BNDX(-9%) UUP(-8%) TLT(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.82% (StdDev 3.64%) | Hourly BBV | 0 () | Intraday Trend | -4.8% | | | |
|
5 Day Moving Average | $39.89(-5.14%) | 10 Day Moving Average | $39.91(-5.19%) | 20 Day Moving Average | $37.43(1.1%) | To recent high | -11.3% | To recent low | 53.4% | Market Cap | $1.07b | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |